Citations

Showing 10 of 108152 citations.

Clinical Efficacy of Liposomal Bupivacaine
Abildgaard, Jeffrey T. , Chung, Andrew S. , Tokish, John M. , Hattrup, Steven J. , Chung, Andrew

Mayo Clinic

JBJS Reviews | July 24, 2019 | Volume: 7 | Issue: 7 | Pages: e8-e8

10.2106/jbjs.rvw.18.00192 | PMID 31343508 Get It

Background: There has been a surge in interest with regard to the utility of liposomal bupivacaine as part of a perioperative pain management protocol. The current study was proposed to critically assess the efficacy of liposomal bupivacaine as a local anesthetic for pain relief following orthopaedic procedures. Methods: A systematic review of prospective, randomized trials involving liposomal bupivacaine was performed using searches of the PubMed, Embase, and Cochrane databases. The primary outcomes of interest included postoperative subjective pain scores and narcotic consumption. The length of stay and postoperative mobility were reviewed as secondary outcomes. Results: Twenty-seven studies met inclusion criteria and were included for review. Twelve of 17 studies concluded that periarticular or local infiltrative liposomal bupivacaine offered no additive benefit compared with other local anesthetic injections. Peripheral nerve blocks without liposomal bupivacaine conferred more optimal pain relief and decreased narcotic consumption in the immediate postoperative period when compared with liposomal bupivacaine, with no differences thereafter. Twelve studies listed a conflict of interest related to the drug manufacturer (Pacira Pharmaceuticals). Eight of these studies (67%) demonstrated clinical superiority of liposomal bupivacaine when compared with the study control. In the 15 studies that did not show a conflict of interest, only 1 study (7%) demonstrated therapeutic superiority with use of periarticular liposomal bupivacaine when compared with a historical cohort that received no local or regional anesthesia. Conclusions: Current prospective, randomized controlled trials in patients undergoing orthopaedic surgery fail to support the routine use of liposomal bupivacaine compared with other local injectable analgesics, particularly in the setting of knee replacement surgery. We were unable to find consistent support for the potential of superior pain relief and narcotic use reduction with the use of liposomal bupivacaine. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
Surgical Management of the Spastic Forearm, Wrist, and Hand: Evidence-Based Treatment Recommendations
Rhee, Peter C. , Rhee, Peter C

Mayo Clinic

JBJS Reviews | July 24, 2019 | Volume: 7 | Issue: 7 | Pages: e5-e5

10.2106/jbjs.rvw.18.00172 | PMID 31343511 Get It

» The surgical approach for the patient with a spastic upper limb must be individualized and goal-focused. » An injury to the central nervous system can lead to spinal reflex hyperexcitability with exaggerated muscle activation in response to quick stretch stimuli (i.e., spasticity). » Surgical treatment options are dependent on the potential for function in the spastic upper limb. » If volitional motor control is present, spastic motor units can be lengthened or released while preserving function. » In the absence of volitional motor control, spastic muscles can be divided, released, or denervated with selective neurectomies.
Esophageal Actinomycosis Presenting as an Obstructive Esophageal Mass
Alshati, Ali , Appleton, Leslie, Maddux, Jacob T., Almohammedawi, Mays, Dangerfield, Benjamin S., Dangerfield, Benjamin

Mayo Clinic

ACG Case Reports Journal | July 24, 2019 | Volume: 6 | Issue: 7 | Pages: e00140

10.14309/crj.0000000000000140 | PMID 31620537 Get It

ABSTRACT Esophageal actinomycosis is a rare type of esophageal infection, with only approximately 24 cases previously reported in the United States. Most of these cases were described as erosions or ulcers when examined endoscopically. We present a 47-year-old woman who presented with dysphagia. Endoscopy showed a lower esophageal fungating mass, mimicking a malignant mass. Although there was a high suspicion of esophageal carcinoma, biopsy results showed esophageal actinomyces infection.
Iatrogenic Bilothorax: A Rare Complication of Orthotopic Liver Transplant
Karnik, Nihaal , Shair, Kamal A.

Mayo Clinic

ACG Case Reports Journal | July 24, 2019 | Volume: 6 | Issue: 7 | Pages: e00137

10.14309/crj.0000000000000137 | PMID 31620534 Get It

ABSTRACT Bilothorax is a rare condition involving drainage of bile from the biliary system into the lung's pleural space. Several cases have been reported in the literature, where the most commonly reported cause is iatrogenic injury. To date, no cases of bilothorax as a complication of liver transplantation have been reported. Given its rarity and concurrent morbidity, early recognition is paramount as this condition can quickly deteriorate into adult respiratory distress syndrome.
Post-operative Orthopedic Infection with Monomicrobial Leclercia adecarboxylata
Mayfield, Cory K. , Haglin, Jack M. , Konda, Sanjit R. , Tejwani, Nirmal C. , Egol, Kenneth A.

Mayo Clinic

JBJS Case Connector | July 24, 2019 | Volume: 9 | Issue: 3 | Pages: e0297-e0297

10.2106/jbjs.cc.18.00297 | PMID 31343997 Get It

Case: An 65-year-old immunocompetent female developed a Leclercia adecarboxylata infection following the repair of closed olecranon fracture. L. adecarboxylata is associated with polymicrobial infections, infections in immunocompromised patients and penetrating or open wounds. Following speciation, intravenous ceftriaxone was started. Two weeks later, the patient presented with leukopenia and neutropenia. Per infectious disease recommendations, the patient was switched to intravenous ertapenem with resolution of both infection and neutropenia. The olecranon fracture went on to heal fully. Conclusions: This case describes a rare postoperative monomicrobial infection with L. adecarboxylata in an immunocompetent host following musculoskeletal trauma and identifies L. adecarboxylata as a potential emerging hospital-acquired pathogen following orthopedic surgery.
The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 24, 2019 | Volume: 200 | Issue: 9 | Pages: 1084-1085

10.1164/rccm.201907-1298ed | PMID 31339740 Get It

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial
Muss, Hyman B. , Polley, Mei‐Yin C. , Berry, Donald A. , Liu, Heshan , Cirrincione, Constance, Theodoulou, Maria, Mauer, Ann M. , Kornblith, Alice B., Dressler, Lynn G., Cohen, Harvey Jay, Kartcheske, Patricia A., Perez, Edith A. , Burstein, Harold J. , Mahmood, Ahmad, Sutton, Linda , Magrinat, Gustav , Parker, Barbara A. , Hart, Ronald D., Grenier, Debjani, Hurria, Arti , Jatoi, Aminah , Hudis, Clifford A. , Partridge, Ann H. , Wolff, Antonio C. , Gralow, Julie R. , Mahmood, Ahmad A., Norton, Larry , Winer, Eric P. , Carey, Lisa A.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2019 | Volume: 37 | Issue: 26 | Pages: 2338-2348

10.1200/jco.19.00647 | PMID 31339827 Get It

PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and Leukemia Group B 49907 trial focused on women age 65 years and older. We previously reported the primary analysis after a median follow-up of 2.4 years. Standard adjuvant chemotherapy showed significant improvements in recurrence-free survival (RFS) and overall survival compared with capecitabine. We now update results at a median follow-up of 11.4 years. PATIENTS AND METHODS Patients age 65 years or older with early breast cancer were randomly assigned to either standard adjuvant chemotherapy (physician’s choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin) or capecitabine. An adaptive Bayesian design was used to determine sample size and test noninferiority of capecitabine. The primary end point was RFS. RESULTS The design stopped accrual with 633 patients at its first sample size assessment. RFS remains significantly longer for patients treated with standard chemotherapy. At 10 years, in patients treated with standard chemotherapy versus capecitabine, the RFS rates were 56% and 50%, respectively (hazard ratio [HR], 0.80; P = .03); breast cancer–specific survival rates were 88% and 82%, respectively (HR, 0.62; P = .03); and overall survival rates were 62% and 56%, respectively (HR, 0.84; P = .16). With longer follow-up, standard chemotherapy remains superior to capecitabine among hormone receptor–negative patients (HR, 0.66; P = .02), but not among hormone receptor–positive patients (HR, 0.89; P = .43). Overall, 43.9% of patients have died (13.1% from breast cancer, 16.4% from causes other than breast cancer, and 14.1% from unknown causes). Second nonbreast cancers occurred in 14.1% of patients. CONCLUSION With longer follow-up, RFS remains superior for standard adjuvant chemotherapy versus capecitabine, especially in patients with hormone receptor–negative disease. Competing risks in this older population dilute overall survival benefits.